The purpose of this study is to find out if various doses of ZE50-0134 can be safely given to participants with CLL or SLL when administered via oral (taken by mouth) capsule.
Thank you for your interest, but this study will start enrolling soon.
United States (Nationwide)
Deborah Stephens
LCCC - Clinical Trials
Clinical or Medical
Interventional
Blood Conditions
Cancer (Lymphoma)
25-0277
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
